Total Asset Turnover
since 2012
Calculation
AbbVie Inc., total asset turnover, long-term trends, calculation
Total asset turnover | = | Net revenues1 | ÷ | Total assets1 | |
---|---|---|---|---|---|
Dec 31, 2019 | 0.37 | = | 33,266 | ÷ | 89,115 |
Dec 31, 2018 | 0.55 | = | 32,753 | ÷ | 59,352 |
Dec 31, 2017 | 0.40 | = | 28,216 | ÷ | 70,786 |
Dec 31, 2016 | 0.39 | = | 25,638 | ÷ | 66,099 |
Dec 31, 2015 | 0.43 | = | 22,859 | ÷ | 53,050 |
Dec 31, 2014 | 0.72 | = | 19,960 | ÷ | 27,547 |
Dec 31, 2013 | 0.64 | = | 18,790 | ÷ | 29,198 |
Dec 31, 2012 | 0.68 | = | 18,380 | ÷ | 27,008 |
Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21), 10-K (filing date: 2013-03-15).
1 US$ in millions
Comparison to Competitors
AbbVie Inc., total asset turnover, long-term trends, comparison to competitors
AbbVie Inc. | Abbott Laboratories | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2019 | 0.37 | 0.47 | 0.37 | 0.20 | 0.57 | 0.36 | 0.48 | 0.52 | 0.55 | 0.31 | 0.53 | 0.50 | 0.54 |
Dec 31, 2018 | 0.55 | 0.46 | 0.34 | 0.64 | 0.56 | 0.34 | 0.48 | 0.53 | 0.51 | 0.34 | 0.57 | 0.49 | 0.54 |
Dec 31, 2017 | 0.40 | 0.36 | 0.27 | 0.62 | 0.51 | 0.37 | 0.52 | 0.49 | 0.46 | 0.31 | 0.67 | 0.70 | 0.62 |
Dec 31, 2016 | 0.39 | 0.40 | 0.28 | 0.58 | 0.55 | 0.53 | 0.56 | 0.51 | 0.42 | 0.31 | 0.70 | 0.59 | 0.64 |
Dec 31, 2015 | 0.43 | 0.49 | 0.29 | 0.52 | 0.56 | 0.62 | 0.60 | 0.53 | 0.39 | 0.29 | 0.73 | 0.41 | 0.60 |
Dec 31, 2014 | 0.72 | 0.49 | 0.28 | 0.47 | 0.53 | 0.71 | 0.56 | 0.57 | 0.43 | 0.29 | 0.73 | 0.25 | 0.72 |
Dec 31, 2013 | 0.64 | 0.51 | 0.28 | 0.42 | 0.66 | 0.48 | 0.47 | 0.54 | 0.42 | 0.30 | 0.71 | 0.52 | 0.70 |
Dec 31, 2012 | 0.68 | 0.59 | 0.31 | 0.49 | 0.66 | 0.44 | 0.45 | 0.55 | 0.45 | 0.32 | 0.66 | 0.55 | 0.69 |
Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21), 10-K (filing date: 2013-03-15).
Comparison to Sector (Pharmaceuticals & Biotechnology)
AbbVie Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals & biotechnology)
AbbVie Inc. | Pharmaceuticals & Biotechnology | |
---|---|---|
Dec 31, 2019 | 0.37 | 0.40 |
Dec 31, 2018 | 0.55 | 0.46 |
Dec 31, 2017 | 0.40 | 0.41 |
Dec 31, 2016 | 0.39 | 0.42 |
Dec 31, 2015 | 0.43 | 0.43 |
Dec 31, 2014 | 0.72 | 0.45 |
Dec 31, 2013 | 0.64 | 0.43 |
Dec 31, 2012 | 0.68 | 0.46 |
Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21), 10-K (filing date: 2013-03-15).
Comparison to Industry (Health Care)
AbbVie Inc., total asset turnover, long-term trends, comparison to industry (health care)
AbbVie Inc. | Health Care | |
---|---|---|
Dec 31, 2019 | 0.37 | 0.51 |
Dec 31, 2018 | 0.55 | 0.57 |
Dec 31, 2017 | 0.40 | 0.51 |
Dec 31, 2016 | 0.39 | 0.53 |
Dec 31, 2015 | 0.43 | 0.51 |
Dec 31, 2014 | 0.72 | 0.56 |
Dec 31, 2013 | 0.64 | 0.54 |
Dec 31, 2012 | 0.68 | 0.55 |
Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21), 10-K (filing date: 2013-03-15).